Roche to Present Evidence on Blood Tests for Alzheimer’s Amyloid

Roche and Genentech plan to present Alzheimer’s disease research at CTAD 2026, including updated early data on trontinemab, details of a Phase III trial in preclinical disease, and a new Phase II trial testing the oral NLRP3 inhibitor RG6434 for early symptomatic disease. Their presentations will also cover clinical and health-economic evidence for Elecsys p-tau217 and p-tau181 blood tests. Separately, a biomarker study found plasma p-tau212 performed similarly to p-tau217 in association with Alzheimer’s pathology and may help detect amyloid changes early, while p-tau205 appeared more useful for later-stage changes. DiamiR will present validation work on APOE genotyping from fingertip-prick dried blood samples. In clinical practice, the FDA-cleared Lumipulse blood test can help identify amyloid plaques in people 55 and older who already have cognitive symptoms, but it is not a standalone diagnostic; earlier testing may help patients plan care and access treatment trials.